Prosecution Insights
Last updated: April 19, 2026

Examiner: FISHER, MELISSA L

Tech Center 1600 • Art Units: 1611 1654 1658

This examiner grants 44% of resolved cases

Performance Statistics

44.2%
Allow Rate
-15.8% vs TC avg
470
Total Applications
+42.3%
Interview Lift
1409
Avg Prosecution Days
Based on 462 resolved cases, 2023–2026

Rejection Statute Breakdown

1.2%
§101 Eligibility
17.5%
§102 Novelty
40.5%
§103 Obviousness
26.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18249858 FUSION PROTEIN TARGETING MITOCHONDRIA, METHOD OF MAKING AND USE THEREOF Non-Final OA UNIVERSITY OF ROCHESTER
18338477 Paclitaxel Prodrug, Preparation Method and Application Thereof Final Rejection WEST CHINA HOSPITAL, SICHUAN UNIVERSITY
18024624 PEPTIDES ENDOWED WITH ANGIOGENIC ACTIVITY Non-Final OA Dompe' Farmaceutici SPA
18359420 DELTA T-CELL OR GAMMA RECEPTOR CHAINS OR PARTS THEREOF FOR TREATING OVARIAN CANCER Non-Final OA Gadeta B.V.
18340863 PEPTIDE HYDROGEL COMPRISING HYDROPHILIC AZIDE-CONTAINING AMINO ACID AND ITS USE Non-Final OA The United States of America, as represented by the Secretary, Department of Health and Human servi
18253485 Method for Treating Antibody-Mediated Rejection Non-Final OA CSL Behring GmbH

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month